HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial.

Thomas BaisEsther MeijerBart J KramersPriya VartMarc VervloetMahdi SalihBert BammensNathalie DemoulinPolina TodorovaRoman-Ulrich MüllerJan HalbritterAlexander PaliegeEmilie Cornec-Le GallBertrand KnebelmannRoser TorraAlbert C M OngFiona E Karet FranklRon T Gansevoort

Published in: Trials (2024)

The HYDRO-PROTECT study will demonstrate whether co-treatment with HCT can improve the renoprotective efficacy and tolerability of tolvaptan in patients with ADPKD.

Keyphrases

polycystic kidney disease
randomized controlled trial
study protocol
end stage renal disease
clinical trial
newly diagnosed
ejection fraction
double blind
open label
chronic kidney disease
prognostic factors
heart failure
placebo controlled
peritoneal dialysis
atrial fibrillation
meta analyses